OPGN - OpGen, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.03

-0.09 (-4.25%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	2.12
Open	2.11
Bid	0.00 x 1300
Ask	3.20 x 1000
Day's Range	1.96 - 2.14
52 Week Range	1.62 - 10.48
Volume	56,089
Avg. Volume	531,188

Market Cap	12.105M
Beta	1.46
PE Ratio (TTM)	N/A
EPS (TTM)	-5.80
Earnings Date	Aug 6, 2018 - Aug 10, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	8.00

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswirelast month
OpGen Modifies Terms of Debt with Merck Global Health Innovation Fund
OpGen, Inc. (OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior Secured Promissory Note (the “Note”), dated June 28, 2017, to extend the maturity of the note and to pay accrued interest through the issuance of shares of common stock. The Note is issued to Merck Global Health Innovation Fund, LLC (Merck GHI).
GlobeNewswirelast month
OpGen Presents Data at ASM Microbe 2018 Demonstrating High Accuracy of Acuitas® for Predicting Antibiotic Resistance in Urine Specimens
OpGen, Inc. (OPGN) today announced the presentation of data from the first phase of its Acuitas® urine clinical verification study demonstrating high accuracy in predicting antibiotic resistance in urine specimens. In the study, remnant urine specimens were provided by Intermountain Healthcare and Beth Israel Deaconess Medical Center and were tested with the Acuitas AMR Gene Panel u5.47 (Research Use Only ‘RUO’) to detect 5 pathogens and 47 resistance genes common to urinary tract infections. From the resulting genetic data, the Acuitas Lighthouse® Software (RUO) then predicted antibiotic resistance with greater than 90% accuracy.
GlobeNewswirelast month
OpGen’s Acuitas® AMR Gene Panel u5.47 Data to be Presented at ASM Microbe 2018
GAITHERSBURG, Md., June 05, 2018-- OpGen, Inc. today announced that data on its Acuitas ® AMR Gene Panel u5.47 and Acuitas Lighthouse ® Knowledgebase will be presented at ASM Microbe 2018 being held June ...
ACCESSWIRE2 months ago
Free Stock Performance Review on Organovo Holdings and Three Additional Medical Research Stocks
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of OPGN earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 OpGen Inc Earnings Call
GlobeNewswire2 months ago
OpGen Reports First Quarter 2018 Financial Results and Provides a Business Update
Revenue increases 10% to $0.8 million, net loss decreases 39% to $3.0 million. Conference call begins at 4:30 p.m. Eastern time today. GAITHERSBURG, Md., May 08, 2018-- OpGen, Inc. today reported financial ...
GlobeNewswire2 months ago
OpGen Announces Date of First Quarter 2018 Financial Results Conference Call
GAITHERSBURG, Md., May 01, 2018-- OpGen, Inc. announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, ...
GlobeNewswire3 months ago
OpGen Highlights Acuitas® Analytical Validation Data for Rapidly Predicting Antibiotic Resistance Using Drug Resistance Gene Profiles at ECCMID
GAITHERSBURG, Md., April 24, 2018-- OpGen, Inc. today announced that it has presented analytical validation results for the Acuitas ® AMR Gene Panel u5.47 for detection of multi-drug resistant pathogens ...
ACCESSWIRE3 months ago
With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move
Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.
GlobeNewswire3 months ago
OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
GAITHERSBURG, Md., April 19, 2018-- OpGen, Inc. OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification ...
Thomson Reuters StreetEvents4 months ago
Edited Transcript of OPGN earnings conference call or presentation 15-Mar-18 8:30pm GMT
Q4 2017 OpGen Inc Earnings Call
ACCESSWIRE4 months ago
OpGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern Time. To listen ...
ACCESSWIRE4 months ago
Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests
Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...
Simply Wall St.4 months ago
Has OpGen Inc (NASDAQ:OPGN) Improved Earnings Growth In Recent Times?
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
American City Business Journals5 months ago
OpGen regains Nasdaq compliance but Wall Street woes continue
OpGen Inc. is back in compliance with Nasdaq's rules, but CEO Evan Jones says the Gaithersburg biotech must do a better job helping the market recognize its value. The molecular diagnostics company (OPGN) staved off its third delisting threat in the last year after making a number of financial moves, including a 1-for-25 reverse stock split to help increase its share price above Nasdaq's $1-per-share minimum, one of the issues that put OpGen at risk. OpGen also priced a $12 million public offering Friday, selling 3.6 million units comprising one share of common stock and one common warrant to purchase one-half share of common stock at $3.25 each.
Simply Wall St.6 months ago
Is OpGen Inc’s (NASDAQ:OPGN) CEO Incentives Align With Yours?
Evan Jones is the CEO of OpGen Inc (NASDAQ:OPGN), which has recently grown to a market capitalization of $9.07M. Understanding how CEOs are incentivised to run and grow their companyRead More...